Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 20/20 | 0.73 |
| ▸ | EGLN2 | Q96KS0 | 14/20 | 0.55 |
| ▸ | THRA | P10827 | 1/20 | 0.50 |
| ▸ | THRB | P10828 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30274419 | 1.00 | EGLN1 (0.73) | EGLN1EGLN2THRATHRB | |
| SCHEMBL1219413 | 0.93 | EGLN1 (0.63) | EGLN1EGLN2 | |
| SCHEMBL30274523 | 0.93 | EGLN1 (0.63) | EGLN1EGLN2 | |
| SCHEMBL1218286 | 0.92 | EGLN1 (0.68) | EGLN1EGLN2THRATHRB | |
| SCHEMBL1218106 | 0.92 | EGLN1 (0.65) | EGLN1EGLN2THRATHRB | |
| SCHEMBL1216349 | 0.92 | EGLN1 (0.62) | EGLN1EGLN2THRATHRB | |
| SCHEMBL1218311 | 0.92 | EGLN1 (0.73) | EGLN1EGLN2THRATHRB | |
| SCHEMBL30274409 | 0.92 | EGLN1 (0.73) | EGLN1EGLN2THRATHRB | |
| SCHEMBL1219127 | 0.91 | EGLN1 (0.60) | EGLN1EGLN2THRATHRB | |
| SCHEMBL1219375 | 0.91 | EGLN1 (0.66) | EGLN1EGLN2THRATHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160015786-A1 | MOBILIZING AGENTS AND USES THEREFOR | MATER MEDICAL RESEARCH INSTITUTE LIMITED (AU) | 2016-01-21 | — | — | US | claimed |
| US-9174976-B2 | Cyanoisoquinoline compounds and methods of use thereof | FIBROGEN, INC. (US) | 2015-11-03 | — | — | US | claimed |
| US-20150031696-A1 | CYANOISOQUINOLINE COMPOUNDS AND METHODS OF USE THEREOF | FIBROGEN, INC. (US) | 2015-01-29 | — | — | US | claimed |
| EP-2822545-A2 | TREATMENT FOR HIGH CHOLESTEROL | Fibrogen, Inc. (US) | 2015-01-14 | — | — | EP | claimed |
| US-8759373-B2 | Cyanoisoquinoline compounds and methods of use thereof | FIBROGEN, INC. (US) | 2014-06-24 | — | — | US | claimed |
| US-20140163061-A1 | Methods For Reducing Blood Pressure | FIBROGEN, INC. (US) | 2014-06-12 | — | — | US | claimed |
| WO-2013134632-A2 | TREATMENT FOR HIGH CHOLESTEROL | FIBROGEN, INC. (US) | 2013-09-12 | — | — | WO | claimed |
| EP-2476669-A1 | Cyanoisoquinoline compounds and methods of use thereof | Fibrogen, Inc. (US) | 2012-07-18 | — | — | EP | claimed |
| US-20120178755-A1 | CYANOISOQUINOLINE COMPOUNDS AND METHODS OF USE THEREOF | FIBROGEN, INC. | 2012-07-12 | — | — | US | claimed |
| EP-2044028-B1 | CYANOISOQUINOLINE COMPOUNDS THAT STABILIZE HYPOXIA INDUCIBLE FACTOR (HIF) | FIBROGEN INC (US) | 2012-05-16 | — | — | EP | claimed |
| US-7928120-B2 | Cyanoisoquinoline compounds and methods of use thereof | FIBROGEN, INC. (US) | 2011-04-19 | — | — | US | claimed |
| US-20110039878-A1 | METHODS FOR REDUCING BLOOD PRESSURE | FIBROGEN, INC. | 2011-02-17 | — | — | US | claimed |
| EP-2222305-A1 | METHODS FOR REDUCING BLOOD PRESSURE | Fibrogen, Inc. (US) | 2010-09-01 | — | — | EP | claimed |
| WO-2009058403-A1 | METHODS FOR REDUCING BLOOD PRESSURE | FIBROGEN, INC. (US) | 2009-05-07 | — | — | WO | claimed |
| EP-2044028-A2 | CYANOISOQUINOLINE COMPOUNDS THAT STABILIZE HYPOXIA INDUCIBLE FACTOR (HIF) | FIBROGEN, INC. (US) | 2009-04-08 | — | — | EP | claimed |
| US-20070298104-A1 | CYANOISOQUINOLINE COMPOUNDS AND METHODS OF USE THEREOF | FIBROGEN, INC. | 2007-12-27 | — | — | US | claimed |
| WO-2007090068-A2 | CYANOISOQUINOLINE COMPOUNDS THAT STABILIZE HYPOXIA INDUCIBLE FACTOR (HIF) | FIBROGEN, INC. (US) | 2007-08-09 | — | — | WO | claimed |
| EP-4142721-A1 | HYPOXIA-INDUCIBLE FACTOR PROLYL HYDROXYLASE INHIBITORS FOR TREATING AGING-RELATED CONDITIONS | Bioage Labs, Inc. (US) | 2023-03-08 | — | — | EP | disclosed |
| WO-2007097929-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF STROKE | FIBROGEN, INC. (US) | 2007-08-30 | — | — | WO | disclosed |
| WO-2007090068-A2 | CYANOISOQUINOLINE COMPOUNDS THAT STABILIZE HYPOXIA INDUCIBLE FACTOR (HIF) | FIBROGEN, INC. (US) | 2007-08-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110039878-A1 | METHODS FOR REDUCING BLOOD PRESSURE | HMGCR, MB, PDE3A | EGLN1 1790/4885EGLN2 284/4885THRA 3513/4885 |
| US-20070298104-A1 | CYANOISOQUINOLINE COMPOUNDS AND METHODS OF USE THEREOF | HIF1AN, HIF1A, EGLN3 | EGLN1 7/4885EGLN2 4/4885THRA 3560/4885 |
| US-20120178755-A1 | CYANOISOQUINOLINE COMPOUNDS AND METHODS OF USE THEREOF | HIF1AN, HIF1A, EGLN3 | EGLN1 7/4885EGLN2 4/4885THRA 3560/4885 |
| US-20140163061-A1 | Methods For Reducing Blood Pressure | HMGCR, MB, PDE3A | EGLN1 1790/4885EGLN2 284/4885THRA 3513/4885 |
| US-20150031696-A1 | CYANOISOQUINOLINE COMPOUNDS AND METHODS OF USE THEREOF | HIF1AN, HIF1A, EGLN3 | EGLN1 7/4885EGLN2 4/4885THRA 3560/4885 |
| US-20160015786-A1 | MOBILIZING AGENTS AND USES THEREFOR | HIF1AN, CXCL12, HIF1A | EGLN1 10/4885EGLN2 6/4885THRA 2892/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.